Inside Astellas' $3B Audentes gene therapy acquisition: coded messages, a bidding war and $77M for the CEO

Jason Mast

Editor

Word of Astellas’ first multibillion-dollar offer was passed in coded language at a palm tree-lined Park Hyatt in San Diego, where one of gene therapy’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Inside Astellas' $3B Audentes gene therapy acquisition: coded messages, a bidding war and $77M for the CEO

Jason Mast

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

In­side Astel­las' $3B Au­dentes gene ther­a­py ac­qui­si­tion: cod­ed mes­sages, a bid­ding war and $77M for the CEO

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Inside Astellas' $3B Audentes gene therapy acquisition: coded messages, a bidding war and $77M for the CEO